PL2833973T3 - Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone - Google Patents

Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone

Info

Publication number
PL2833973T3
PL2833973T3 PL13728551T PL13728551T PL2833973T3 PL 2833973 T3 PL2833973 T3 PL 2833973T3 PL 13728551 T PL13728551 T PL 13728551T PL 13728551 T PL13728551 T PL 13728551T PL 2833973 T3 PL2833973 T3 PL 2833973T3
Authority
PL
Poland
Prior art keywords
inhibitors
compounds useful
combination therapies
atr kinase
atr
Prior art date
Application number
PL13728551T
Other languages
English (en)
Polish (pl)
Inventor
John Robert Pollard
Philip Michael Reaper
Mohammed Asmal
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL2833973T3 publication Critical patent/PL2833973T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13728551T 2012-04-05 2013-04-05 Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone PL2833973T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261620717P 2012-04-05 2012-04-05
PCT/US2013/035466 WO2013152298A1 (en) 2012-04-05 2013-04-05 Compounds useful as inhibitors of atr kinase and combination therapies thereof
EP13728551.6A EP2833973B1 (en) 2012-04-05 2013-04-05 Compounds useful as inhibitors of atr kinase and combination therapies thereof

Publications (1)

Publication Number Publication Date
PL2833973T3 true PL2833973T3 (pl) 2018-02-28

Family

ID=48614105

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13728551T PL2833973T3 (pl) 2012-04-05 2013-04-05 Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone

Country Status (22)

Country Link
US (4) US20140044802A1 (enExample)
EP (2) EP3311816A1 (enExample)
JP (4) JP2015515478A (enExample)
CN (2) CN104582795B (enExample)
AU (2) AU2013243291B2 (enExample)
CA (1) CA2869309C (enExample)
DK (1) DK2833973T3 (enExample)
ES (1) ES2654670T3 (enExample)
HK (1) HK1205028A1 (enExample)
HR (1) HRP20171915T1 (enExample)
HU (1) HUE035253T2 (enExample)
IN (1) IN2014KN02410A (enExample)
LT (1) LT2833973T (enExample)
MX (1) MX358818B (enExample)
NO (1) NO2885404T3 (enExample)
NZ (3) NZ726671A (enExample)
PL (1) PL2833973T3 (enExample)
PT (1) PT2833973T (enExample)
RS (1) RS56673B1 (enExample)
SI (1) SI2833973T1 (enExample)
TW (2) TWI644672B (enExample)
WO (1) WO2013152298A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376485B1 (en) 2008-12-19 2017-12-06 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
KR20130066633A (ko) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
BR112014007690B1 (pt) 2011-09-30 2022-10-04 Vertex Pharmaceuticals Incorporated Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas
CN103987709B (zh) 2011-09-30 2016-09-28 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
EP3311816A1 (en) 2012-04-05 2018-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase for the treatment of cancer
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
PL3077397T3 (pl) 2013-12-06 2020-04-30 Vertex Pharmaceuticals Inc. Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
RU2705156C2 (ru) 2014-08-22 2019-11-05 Кловис Онколоджи, Инк. Таблетки, содержащие большую дозу рукапариба
RU2768621C1 (ru) * 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
EP3399983A1 (en) * 2016-01-08 2018-11-14 The Institute of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
US10570119B2 (en) 2016-01-11 2020-02-25 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
AR110995A1 (es) 2017-02-24 2019-05-22 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
WO2018187479A1 (en) 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
CA3071760A1 (en) 2017-08-04 2019-02-07 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3720973A1 (en) 2017-12-08 2020-10-14 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
BR112021004935A2 (pt) 2018-09-26 2021-06-01 Merck Patent Gmbh combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer
EP3866785A1 (en) 2018-10-15 2021-08-25 Merck Patent GmbH Combination therapy utilizing dna alkylating agents and atr inhibitors
CA3116230A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
EP3873905A4 (en) 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING COMPOUNDS AND THEIR USE AS KINASE ATR INHIBITORS
CA3148767A1 (en) * 2019-07-26 2021-02-04 Health Research, Inc. Treatment of p53-deficient cancers
WO2022103827A1 (en) * 2020-11-10 2022-05-19 New Mexico Tech University Research Park Corporation Kp372-1-induced dna damage as a chemotherapeutic approach to treat cancer
CN117024413B (zh) * 2023-10-07 2024-01-09 天津匠新致成科技有限公司 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
JPS62270623A (ja) 1985-12-07 1987-11-25 Daicel Chem Ind Ltd ビス（４−アミノフエニル）ピラジンおよびその製法、ならびにポリイミドおよびその製法
JPS63208520A (ja) 1987-02-26 1988-08-30 Terumo Corp ピラジン誘導体を含有する血小板凝集抑制剤
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JPH0272370A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0272372A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0374370A (ja) 1989-08-16 1991-03-28 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
JP2597917B2 (ja) 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
US5572248A (en) 1994-09-19 1996-11-05 Teleport Corporation Teleconferencing method and system for providing face-to-face, non-animated teleconference environment
EP0914318A1 (en) 1996-05-11 1999-05-12 Kings College London Pyrazines
JP4026876B2 (ja) 1996-09-05 2007-12-26 日本食品化工株式会社 発光性シクロデキストリン誘導体及びその製造方法
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
WO1999044609A1 (en) 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
KR20010071936A (ko) 1998-07-16 2001-07-31 시오노 요시히코 항종양 활성을 갖는 피리미딘 유도체
US7023913B1 (en) 2000-06-14 2006-04-04 Monroe David A Digital security multimedia sensor
US6790935B1 (en) 1999-02-05 2004-09-14 Debiopharm S.A. Cyclosporin derivatives and method for the production of said derivatives
US6738073B2 (en) 1999-05-12 2004-05-18 Imove, Inc. Camera system with both a wide angle view and a high resolution view
AU6051800A (en) 1999-06-16 2001-01-02 University Of Iowa Research Foundation, The Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US7015954B1 (en) 1999-08-09 2006-03-21 Fuji Xerox Co., Ltd. Automatic video system using multiple cameras
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE384704T1 (de) 1999-12-17 2008-02-15 Novartis Vaccines & Diagnostic Pyrazin-basierte hemmer der glycogen-synthase- kinase 3
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US6829391B2 (en) 2000-09-08 2004-12-07 Siemens Corporate Research, Inc. Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US8085293B2 (en) 2001-03-14 2011-12-27 Koninklijke Philips Electronics N.V. Self adjusting stereo camera system
US6759657B2 (en) 2001-03-27 2004-07-06 Kabushiki Kaisha Toshiba Infrared sensor
WO2002080899A1 (fr) 2001-03-30 2002-10-17 Eisai Co., Ltd. Agent de traitement de maladie digestive
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
DE60229059D1 (de) 2001-05-08 2008-11-06 Univ Yale Proteomimetische verbindungen und verfahren
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP2005508321A (ja) 2001-09-26 2005-03-31 メルク　エンド　カムパニー　インコーポレーテッド 結晶形態のエルタペネムナトリウム
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
PT1446387E (pt) 2001-11-21 2009-12-21 Pharmacia & Upjohn Co Llc Derivados de aril-1,4-pirazina substituídos
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
MXPA04007697A (es) 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
KR20040090978A (ko) 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7043079B2 (en) 2002-04-25 2006-05-09 Microsoft Corporation “Don't care” pixel interpolation
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20040075741A1 (en) 2002-10-17 2004-04-22 Berkey Thomas F. Multiple camera image multiplexer
US7385626B2 (en) 2002-10-21 2008-06-10 Sarnoff Corporation Method and system for performing surveillance
US20040100560A1 (en) 2002-11-22 2004-05-27 Stavely Donald J. Tracking digital zoom in a digital video camera
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
AU2004215428B2 (en) 2003-02-26 2009-08-27 Sugen LLC Aminoheteroaryl compounds as protein kinase inhibitors
US7684624B2 (en) 2003-03-03 2010-03-23 Smart Technologies Ulc System and method for capturing images of a target area on which information is recorded
DE602004015429D1 (de) 2003-03-11 2008-09-11 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
JP2006520794A (ja) 2003-03-21 2006-09-14 スミスクライン ビーチャム コーポレーション 化合物
CN101468965A (zh) 2003-03-24 2009-07-01 默克公司 联芳基取代的6元杂环钠通道阻滞剂
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
GB2400514B (en) 2003-04-11 2006-07-26 Hewlett Packard Development Co Image capture method
JP2006528980A (ja) 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
WO2004103991A1 (en) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. 2-substituted piperidines, focused library and a pharmaceutical compound
US20050123902A1 (en) 2003-05-21 2005-06-09 President And Fellows Of Harvard College Human papillomavirus inhibitors
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US7986339B2 (en) 2003-06-12 2011-07-26 Redflex Traffic Systems Pty Ltd Automated traffic violation monitoring and reporting system with combined video and still-image data
JP2005020227A (ja) 2003-06-25 2005-01-20 Pfu Ltd 画像圧縮装置
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
US20050116968A1 (en) 2003-12-02 2005-06-02 John Barrus Multi-capability display
WO2005058876A1 (en) 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
US20050276765A1 (en) 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1778687A2 (en) 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
MX2007002312A (es) 2004-08-26 2007-04-16 Pfizer Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa.
US7730406B2 (en) 2004-10-20 2010-06-01 Hewlett-Packard Development Company, L.P. Image processing system and method
JP5008569B2 (ja) 2004-10-22 2012-08-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼのインヒビターとしての芳香族アミド
WO2006053342A2 (en) 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
US20060122185A1 (en) 2004-11-22 2006-06-08 Jeremy Green Bicyclic inhibitors of Rho kinase
JP4810669B2 (ja) 2004-11-25 2011-11-09 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
CA2590261C (en) 2004-12-27 2011-08-16 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
PE20061093A1 (es) 2005-02-16 2006-11-10 Schering Corp Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3
JP5033119B2 (ja) 2005-04-25 2012-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ阻害剤としての新規アザ複素環化合物
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006135604A2 (en) 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
KR20080040692A (ko) 2005-08-02 2008-05-08 렉시컨 파마슈티컬스 인코퍼레이티드 단백질 키나제 억제제로서의 2-아미노아릴 피리딘
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
US7394926B2 (en) 2005-09-30 2008-07-01 Mitutoyo Corporation Magnified machine vision user interface
US7806604B2 (en) 2005-10-20 2010-10-05 Honeywell International Inc. Face detection and tracking in a wide field of view
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
AU2006319247B2 (en) 2005-12-01 2010-03-11 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors
US7871982B2 (en) 2005-12-09 2011-01-18 Meiji Seika Kaisha, Ltd. Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient
US20090143410A1 (en) 2005-12-14 2009-06-04 Kanu Maganbhai Patel Isoxazolines for Controlling Invertebrate Pests
RU2008130111A (ru) 2005-12-22 2010-01-27 Алькон Рисерч, Лтд. (Us) (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
EP2004625B1 (en) 2006-03-22 2009-12-30 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
US7574131B2 (en) 2006-03-29 2009-08-11 Sunvision Scientific Inc. Object detection system and method
JP2009532356A (ja) 2006-03-31 2009-09-10 シェーリング コーポレイション キナーゼ阻害物質
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
CA2655857C (en) 2006-06-22 2014-12-02 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
ATE456565T1 (de) 2006-06-22 2010-02-15 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
CA2664119A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
MX2009004077A (es) 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
CN101600714B (zh) 2006-11-10 2013-08-21 百时美施贵宝公司 吡咯并吡啶激酶抑制剂
US20080132698A1 (en) 2006-11-30 2008-06-05 University Of Ottawa Use of N-oxide compounds in coupling reactions
WO2008071456A2 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US7687522B2 (en) 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EA019951B1 (ru) 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
JP2008260691A (ja) 2007-04-10 2008-10-30 Bayer Cropscience Ag 殺虫性アリールイソオキサゾリン誘導体
WO2008122375A2 (en) 2007-04-10 2008-10-16 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008146035A1 (en) * 2007-05-25 2008-12-04 Astrazeneca Ab Combination of chk and parp inhibitors for the treatment of cancers
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
EP2012409A2 (en) 2007-06-19 2009-01-07 Hitachi, Ltd. Rotating electrical machine
WO2008156174A1 (ja) 2007-06-21 2008-12-24 Taisho Pharmaceutical Co., Ltd. ピラジンアミド化合物
KR20100037047A (ko) 2007-06-26 2010-04-08 렉시컨 파마슈티컬스 인코퍼레이티드 세로토닌-매개 질환 및 장애의 치료 방법
WO2009005638A2 (en) 2007-06-27 2009-01-08 Merck & Co., Inc. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
JP2010533736A (ja) 2007-07-19 2010-10-28 ハー・ルンドベック・アクチエゼルスカベット ５員複素環アミドおよび関連化合物
KR101552742B1 (ko) 2007-07-19 2015-09-11 머크 샤프 앤드 돔 코포레이션 단백질 키나제 억제제로서의 헤테로사이클릭 아미드 화합물
EA201000113A1 (ru) 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
MX2010004491A (es) 2007-10-25 2010-06-21 Astrazeneca Ab Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
DK2250172T3 (da) 2008-02-25 2012-01-16 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitorer
EP2247595B1 (en) 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
RU2503676C2 (ru) 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
ATE519763T1 (de) 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
JP2011513332A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
EP2328890B1 (en) 2008-08-06 2012-01-25 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
WO2010017055A2 (en) 2008-08-06 2010-02-11 Lead Therapeutics, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
CN102317277A (zh) 2008-10-21 2012-01-11 沃泰克斯药物股份有限公司 C-met蛋白激酶抑制剂
EP2370424A1 (en) 2008-11-10 2011-10-05 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8877772B2 (en) 2008-11-25 2014-11-04 University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
CN102232076B (zh) 2008-12-05 2014-12-31 霍夫曼-拉罗奇有限公司 吡咯并吡嗪基脲激酶抑制剂
EP2376485B1 (en) 2008-12-19 2017-12-06 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
US8785445B2 (en) 2008-12-22 2014-07-22 Array Biopharma Inc. 7-phenoxychroman carboxylic acid derivatives
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
RU2529860C2 (ru) 2009-01-30 2014-10-10 Тояма Кемикал Ко., Лтд. Производное n-ацилантраниловой кислоты или его соль
JP5353279B2 (ja) 2009-02-06 2013-11-27 Ｊｎｃ株式会社 セレンテラミド又はその類縁体の製造方法
BRPI1008020A2 (pt) 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
JP2012522013A (ja) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MX2012000711A (es) 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopirazina de cinasas.
CN102548411B (zh) 2009-08-07 2014-07-02 陶氏益农公司 杀虫组合物
JP2011042639A (ja) 2009-08-24 2011-03-03 Kowa Co ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
DK3070077T3 (en) 2009-10-06 2019-04-01 Millennium Pharm Inc HETEROCYCLIC COMPOUNDS USING PDK1 INHIBITORS
US9205091B2 (en) * 2009-11-13 2015-12-08 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
EP2526090B1 (en) 2010-01-18 2015-08-19 MMV Medicines for Malaria Venture New anti-malarial agents
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CN102933563A (zh) 2010-04-08 2013-02-13 Ah美国42有限责任公司 作为杀虫剂和杀螨剂的取代的3,5-二苯基异噁唑啉衍生物
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
EP2569286B1 (en) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569284B1 (en) 2010-05-12 2015-07-08 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
KR20130066633A (ko) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
CA2798970A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
CA2799904A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
WO2011163527A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
JP5782238B2 (ja) 2010-07-30 2015-09-24 ルネサスエレクトロニクス株式会社 電圧検出回路及びその制御方法
US8962623B2 (en) 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
AU2012225805B2 (en) 2011-03-04 2017-03-02 Lexicon Pharmaceuticals, Inc. MST1 kinase inhibitors and methods of their use
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
AU2012255792A1 (en) 2011-05-17 2013-11-07 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
IN2014KN00943A (enExample) * 2011-09-30 2015-08-21 Vertex Pharma
BR112014007690B1 (pt) 2011-09-30 2022-10-04 Vertex Pharmaceuticals Incorporated Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103987709B (zh) 2011-09-30 2016-09-28 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP3311816A1 (en) 2012-04-05 2018-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase for the treatment of cancer
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
PL3077397T3 (pl) 2013-12-06 2020-04-30 Vertex Pharmaceuticals Inc. Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr

Also Published As

Publication number Publication date
IN2014KN02410A (enExample) 2015-05-01
EP3311816A1 (en) 2018-04-25
EP2833973B1 (en) 2017-09-13
HUE035253T2 (en) 2018-05-02
RS56673B1 (sr) 2018-03-30
JP2018150379A (ja) 2018-09-27
NZ726671A (en) 2018-04-27
US20220233521A1 (en) 2022-07-28
LT2833973T (lt) 2018-02-12
TWI644672B (zh) 2018-12-21
CA2869309C (en) 2021-02-09
CN108478577A (zh) 2018-09-04
US20160030424A1 (en) 2016-02-04
TW201740949A (zh) 2017-12-01
JP2020196748A (ja) 2020-12-10
ES2654670T3 (es) 2018-02-14
MX2014011908A (es) 2014-11-25
SI2833973T1 (en) 2018-04-30
HRP20171915T1 (hr) 2018-02-09
NZ700580A (en) 2016-07-29
HK1205028A1 (en) 2015-12-11
DK2833973T3 (en) 2018-01-02
MX358818B (es) 2018-09-05
US10478430B2 (en) 2019-11-19
CN104582795B (zh) 2018-04-20
CA2869309A1 (en) 2013-10-10
WO2013152298A1 (en) 2013-10-10
JP2017186385A (ja) 2017-10-12
HK1206298A1 (en) 2016-01-08
AU2013243291A1 (en) 2014-10-23
NO2885404T3 (enExample) 2018-09-22
TW201406375A (zh) 2014-02-16
CN104582795A (zh) 2015-04-29
US20200222392A1 (en) 2020-07-16
PT2833973T (pt) 2017-12-21
EP2833973A1 (en) 2015-02-11
US20140044802A1 (en) 2014-02-13
JP2015515478A (ja) 2015-05-28
AU2018200562A1 (en) 2018-02-15
US11110086B2 (en) 2021-09-07
AU2013243291B2 (en) 2018-02-01
JP6770490B2 (ja) 2020-10-14
NZ720511A (en) 2016-12-23

Similar Documents

Publication Publication Date Title
LT2833973T (lt) Junginiai, tinkami naudoti kaip atr kinazės inhibitoriai, ir jų kombinuotas gydymas
IL263262B (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
EP2776837A4 (en) COMBINATION OF KINASEINHIBITORS AND THEIR USE
ZA201502783B (en) Azaquinazoline inhibitors of atypical protein kinase c
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201405140B (en) Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors
IL238728A0 (en) Pyrrolopyrimidine compounds as kinase inhibitors
ZA201501615B (en) Pyrazolopyrimidine compounds as kinase inhibitors
ZA201208373B (en) Compounds useful as inhibitors of atr kinase
LT2820009T (lt) Serino (treonino) kinazės inhibitoriai
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
EP2847186A4 (en) SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER
EP2900243A4 (en) BICYCLIC OXA LACTAM KINASE HEMMER
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors
GB201323021D0 (en) Use of kinase inhibitors
GB201321227D0 (en) Use of kinase inhibitors
GB201309603D0 (en) Novel compounds and their use as kinase inhibitors
GB201305741D0 (en) Novel compounds and their use as kinase inhibitors